Journal article

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Marika Ciprotti, Niall C Tebbutt, Fook-Thean Lee, Sze-Ting Lee, Hui K Gan, David C McKee, Graeme J O'Keefe, Sylvia J Gong, Geoffrey Chong, Wendie Hopkins, Bridget Chappell, Fiona E Scott, Martin W Brechbiel, Archie N Tse, Mendel Jansen, Manabu Matsumura, Masakatsu Kotsuma, Rira Watanabe, Ralph Venhaus, Robert A Beckman Show all

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2015

Abstract

PURPOSE: CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake, and antitumor response in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC who had received at least one course of chemotherapy were assigned to one of five dosage cohorts and infused with a weekly dose of CS-1008. Day 1 and day 36 doses were trace-labeled with indium-111 ((111)In), followed by whole-body planar and regional single-photon emission computed tomography (SPECT) imaging at several time poi..

View full abstract